Literature DB >> 30039447

Specific Medicare Severity-Diagnosis Related Group Codes Increase the Predictability of 30-Day Unplanned Hospital Readmission After Pancreaticoduodenectomy.

Dimitrios Xourafas1,2, Katiuscha Merath2, Gaya Spolverato2, Stanley W Ashley1, Jordan M Cloyd2, Timothy M Pawlik3,4.   

Abstract

BACKGROUND: The Medicare Severity-Diagnosis Related Group coding system (MS-DRG) is routinely used by hospitals for reimbursement purposes following pancreatic surgery. We aimed to determine whether specific pancreatectomy MS-DRG codes, when combined with distinct clinicopathologic and perioperative characteristics, increased the accuracy of predicting 30-day readmission after pancreaticoduodenectomy (PD).
METHODS: Demographic, clinicopathologic, and perioperative factors were compared between readmitted and non-readmitted patients at Brigham and Women's Hospital following PD. Different pancreatectomy DRG codes, currently used for reimbursement purposes [407: without complication/co-morbidity (CC), 406: with CC, and 405: with major CC] were combined with clinical factors to assess their predictability of readmission. Univariate and multivariable analyses were performed to evaluate outcomes.
RESULTS: Among 354 patients who underwent PD between 2010 and 2017, 69 (19%) were readmitted. The incidence of readmission was 13, 32, and 55% for patients with assigned DRG codes 407, 406, and 405, respectively (P = 0.0395). Readmitted patients were more likely to have had T4 disease (P = 0.0007), a vascular resection (P = 0.0078), and longer operative times (P = 0.012). On multivariable analysis, combining DRG 407 with relevant clinicopathologic factors was unable to predict readmission. In contrast, DRG 406 code among patients with N positive disease (P = 0.0263) and LOS > 10 days (P = 0.0505) was associated with readmission. DRG 405, preoperative obstructive jaundice (OR: 7.5, CI: 1.5-36, P = 0.0130), vascular resection (OR: 7.7, CI: 1.1-51, P = 0.0336), N positive stage of disease (OR: 0.2, CI: 0-0.9, P = 0.0447), and operative time > 410 min (OR: 5.9, CI: 1-32, P = 0.0399) were each strongly associated with 30-day readmission after PD [likelihood ratio (LR) < 0.0001].
CONCLUSIONS: Distinct pancreatectomy MS-DRG classification codes (405), combined with relevant clinicopathologic and perioperative characteristics, strongly predicted 30-day readmission after PD. DRG classification algorithms can be implemented to more accurately identify patients at a higher risk of readmission.

Entities:  

Keywords:  Diagnosis Related Group (DRG) codes; Pancreaticoduodenectomy; Predictors; Readmission

Mesh:

Year:  2018        PMID: 30039447     DOI: 10.1007/s11605-018-3879-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

1.  Are all readmissions bad readmissions?

Authors:  Eiran Z Gorodeski; Randall C Starling; Eugene H Blackstone
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Determinants of long-term survival after major surgery and the adverse effect of postoperative complications.

Authors:  Shukri F Khuri; William G Henderson; Ralph G DePalma; Cecilia Mosca; Nancy A Healey; Dharam J Kumbhani
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

3.  Hospital readmission after a pancreaticoduodenectomy: an emerging quality metric?

Authors:  Zachary J Kastenberg; John M Morton; Brendan C Visser; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

4.  A novel risk scoring system reliably predicts readmission after pancreatectomy.

Authors:  Vicente Valero; Joshua C Grimm; Arman Kilic; Russell L Lewis; Jeffrey J Tosoian; Jin He; James F Griffin; John L Cameron; Matthew J Weiss; Charles M Vollmer; Christopher L Wolfgang
Journal:  J Am Coll Surg       Date:  2015-01-08       Impact factor: 6.113

5.  Diagnosis related groups: product line management within hospitals.

Authors:  R B Fetter; J L Freeman
Journal:  Acad Manage Rev       Date:  1986-01

6.  Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies.

Authors:  Eric B Schneider; Omar Hyder; Christopher L Wolfgang; Kenzo Hirose; Michael A Choti; Martin A Makary; Joseph M Herman; John L Cameron; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

7.  Preventable readmissions to surgical services: lessons learned and targets for improvement.

Authors:  Aaron J Dawes; Greg D Sacks; Marcia M Russell; Anne Y Lin; Melinda Maggard-Gibbons; Deborah Winograd; Hallie R Chung; Areti Tillou; Jonathan R Hiatt; Clifford Ko
Journal:  J Am Coll Surg       Date:  2014-04-13       Impact factor: 6.113

8.  The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer.

Authors:  Ryan D Nipp; Areej El-Jawahri; Samantha M Moran; Sara M D'Arpino; P Connor Johnson; Daniel E Lage; Risa L Wong; William F Pirl; Lara Traeger; Inga T Lennes; Barbara J Cashavelly; Vicki A Jackson; Joseph A Greer; David P Ryan; Ephraim P Hochberg; Jennifer S Temel
Journal:  Cancer       Date:  2017-10-23       Impact factor: 6.860

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Readmission after pancreatectomy for pancreatic cancer in Medicare patients.

Authors:  Deepthi M Reddy; Courtney M Townsend; Yong-Fang Kuo; Jean L Freeman; James S Goodwin; Taylor S Riall
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

View more
  1 in total

1.  The Severity of Postoperative Pancreatic Fistula Predicts 30-Day Unplanned Hospital Visit and Readmission after Pancreaticoduodenectomy: A Single-Center Retrospective Cohort Study.

Authors:  Hao-Wei Kou; Chih-Po Hsu; Yi-Fu Chen; Jen-Fu Huang; Shih-Chun Chang; Chao-Wei Lee; Shang-Yu Wang; Chun-Nan Yeh; Ta-Sen Yeh; Tsann-Long Hwang; Jun-Te Hsu
Journal:  Healthcare (Basel)       Date:  2022-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.